COMMUNIQUÉS West-GlobeNewswire

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
27/09/2024
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype [...]
Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
27/09/2024
Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est indiqué à environ 300 000 adultes aux États-Unis présentant une BPCO inadéquatement contrôlée et un [...]
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
27/09/2024
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract manufacturer and expanding [...]
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
27/09/2024
28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75 Three additional data presentations further support ESK-001’s potential to offer a [...]
Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance
27/09/2024
TAMPA, FL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Turning Point of Tampa, a top-rated addiction treatment facility since 1987, is proud to announce that it is now in-network with Blue Cross Blue Shield, effective September [...]
Burning Rock Announces Changes to Management and Board of Directors
27/09/2024
GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in [...]
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
27/09/2024
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the [...]
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
27/09/2024
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
27/09/2024
Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film Outlines the development strategy for the Company’s [...]
TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
27/09/2024
Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly dosing , s upporting the combinability of the GPRC5 D bispecific antibody 1 Safety [...]
Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease
27/09/2024
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies 1 BEERSE, BELGIUM, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag [...]
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
27/09/2024
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population Study design intended to enable supplemental [...]
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
27/09/2024
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ET OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or [...]
33 Medical Wins 2024 Best Technology in Spine Award for Innovative NuvoDisc® Device
27/09/2024
Boca Raton, FL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- 33 Medical, Inc., a leader in cutting-edge spinal health innovations, is proud to announce that its NuvoDisc ® medical device has been awarded the prestigious 2024 Best [...]
WeightWatchers Announces Executive Leadership Transition
27/09/2024
Independent Board Member Tara Comonte Will Serve as Interim Chief Executive Officer Sima Sistani Will Step Down as CEO and Director NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“ [...]
ImPact Biotech Announces 50% Enrollment in Phase 3 ENLIGHTED Clinical Trial of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
27/09/2024
Phase 3 ENLIGHTED study enrollment completion expected by first quarter of 2025 TEL AVIV, Israel, Sept. 27, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing [...]
Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed
27/09/2024
GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital
27/09/2024
– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor group – – Eliminating $12 million in scheduled debt payments through June 2026 – – $11.5 [...]
Venus Concept Announces $15 million Debt-to-Equity Exchange Transaction
27/09/2024
Second Substantial Reduction of Existing Debt by Madryn Asset Management in 2024; the Company has reduced its debt balance by 54% year-to-date TORONTO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus [...]

Pages